· By Sanofi Admin

Drug Development 101: Phase 3 Clinical Trials

This post was authored by Terttu Haring, Vice President in Clinical Sciences & Operations, Global Head Trial Operations, Sanofi
If you have been following along with our Drug Development 101 blog series, you will know that we shed light on preclinical research, Phase 1 clinical trials and Phase 2 clinical trials over the course of past […]

VIEW FULL POST
 · By Sanofi Admin

Sanofi Launches Digital Clinical Trials to Improve Recruitment and Reduce Trial Times

Science 37 Logo

Without clinical trials, new medicine may never make it from the research lab to patients in need. These carefully designed studies can provide important data that include proper dosage, benefit to patients, and potential side effects.
There is a growing challenge, however, in finding appropriate participants, especially for treatments that target highly specific conditions affecting narrower […]

VIEW FULL POST
 · By Sanofi Admin

Drug Development 101: Phase 2 Clinical Trials

Author: Kristin Schuhwerk, VP, Global Head of Clinical Operations, Sanofi
This past November, my colleague Paul Deutsch shared some valuable information about Phase 1 clinical trials, as part of our Drug Development 101 series. Today, I’d like to build on this information by providing some insight on what comes after Phase 1 clinical trials – Phase […]

VIEW FULL POST
 · By Sanofi Admin

Imagine – Innovate – Inspire: Science Offsite Celebrates Great Science for 20th Year

Jim Burns

This post was authored by Jim Burns, Head of North America R&D Hub for Sanofi.
Jim Burns
For the past twenty years, I’ve been part of an amazing tradition where Sanofi’s scientists come together to share their research and discoveries. This annual event, known as the Science Offsite, brings together scientists from our R&D community across all […]

VIEW FULL POST